The 8 Most Exciting Drugs in the 2019 Pipeline

According to Nektar, this is because NKTR-181 does not produce the same high levels of euphoria present in other opioids-it has a low permeability across the blood/brain barrier. According to Sadeghi, there are 10 million with osteoporosis in the U.S. currently, with another 18 million people at ris...

Full description

Saved in:
Bibliographic Details
Published in:Managed Healthcare Executive 2019-01, Vol.29 (1), p.19-20
Main Author: Hamm, Nicholas
Format: Article
Language:English
Subjects:
Diabetes
Drugs
Food allergies
Gene therapy
Mental depression
Narcotics
Osteoporosis
Patients
Psoriasis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to Nektar, this is because NKTR-181 does not produce the same high levels of euphoria present in other opioids-it has a low permeability across the blood/brain barrier. According to Sadeghi, there are 10 million with osteoporosis in the U.S. currently, with another 18 million people at risk. According to Pharma Intelligence, the osteoporosis market will be around $4.1 billion in five years, Evenity could capture around $550 million of that. â–ˇ Nicholas Hamm is an editor with Managed Healthcare Executive Esketamine nasal spray Company: Janssen, PDUFA: 3/4/2019 Indication: Nasal spray for treatment-resistant severe depression.
ISSN:1533-9300
2150-7120